217 related articles for article (PubMed ID: 15203092)
1. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond.
Leeder JS
Drug Discov Today; 2004 Jul; 9(13):567-73. PubMed ID: 15203092
[TBL] [Abstract][Full Text] [Related]
2. Developmental and pediatric pharmacogenomics.
Leeder JS
Pharmacogenomics; 2003 May; 4(3):331-41. PubMed ID: 12718723
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics in drug discovery and development: a translational perspective.
Roses AD
Nat Rev Drug Discov; 2008 Oct; 7(10):807-17. PubMed ID: 18806753
[TBL] [Abstract][Full Text] [Related]
5. The role of genomics in prevention or reducing the impact of congenital malformations.
Shawky RM; Sadik DI
Genet Couns; 2011; 22(2):135-41. PubMed ID: 21848005
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics: bench to bedside.
Weinshilboum R; Wang L
Nat Rev Drug Discov; 2004 Sep; 3(9):739-48. PubMed ID: 15340384
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics: the implementation phase.
Sadee W
AAPS PharmSci; 2002; 4(2):E5. PubMed ID: 12141268
[TBL] [Abstract][Full Text] [Related]
8. Application of pharmacogenomic strategies to the study of drug-induced birth defects.
Leeder JS; Mitchell AA
Clin Pharmacol Ther; 2007 Apr; 81(4):595-9. PubMed ID: 17314924
[TBL] [Abstract][Full Text] [Related]
9. Implications of pharmacogenomics for drug development and clinical practice.
Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of osteoporosis: opportunities and challenges.
Nguyen TV; Eisman JA
J Musculoskelet Neuronal Interact; 2006; 6(1):62-72. PubMed ID: 16675890
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics and therapeutic strategies for dementia.
Cacabelos R
Expert Rev Mol Diagn; 2009 Sep; 9(6):567-611. PubMed ID: 19732004
[TBL] [Abstract][Full Text] [Related]
12. Drug discovery, drug development and the emerging world of pharmacogenomics: prospecting for information in a data-rich landscape.
Michelson S; Joho K
Curr Opin Mol Ther; 2000 Dec; 2(6):651-4. PubMed ID: 11249742
[TBL] [Abstract][Full Text] [Related]
13. Genetic factors in preterm birth--the future.
Esplin MS; Varner MW
BJOG; 2005 Mar; 112 Suppl 1():97-102. PubMed ID: 15715605
[TBL] [Abstract][Full Text] [Related]
14. Beyond genomics.
Dollery CT
Clin Pharmacol Ther; 2007 Oct; 82(4):366-70. PubMed ID: 17851575
[TBL] [Abstract][Full Text] [Related]
15. Progress in pharmacogenomics and its promise for medicine.
Blake CA; Sobel BE
Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
Cacabelos R
Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
[TBL] [Abstract][Full Text] [Related]
17. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
18. Measuring the value of pharmacogenomics.
Phillips KA; Van Bebber SL
Nat Rev Drug Discov; 2005 Jun; 4(6):500-9. PubMed ID: 15915153
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics and drug development: the path to safer and more effective drugs.
Roses AD
Nat Rev Genet; 2004 Sep; 5(9):645-56. PubMed ID: 15372086
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics in cardiovascular clinical trials.
Shah R; Darne B; Atar D; Abadie E; Adams KF; Zannad F;
Fundam Clin Pharmacol; 2004 Dec; 18(6):705-8. PubMed ID: 15548243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
